GSTP1, APC and RASSF1 gene methylation in prostate cancer samples: comparative analysis of MS-HRM method and Infinium HumanMethylation450 BeadChip beadchiparray diagnostic value

   
Skorodumova L.O.1 , Babalyan K.A.2, Sultanov R.2, Vasiliev A.O.3, Govorov A.V.3, Pushkar D.Y.3, Prilepskaya E.A.3, Danilenko S.A.1, Generozov E.V.1, Larin A.K.1, Kostryukova E.S.4, Sharova E.I.1

1. Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia
2. Moscow Institute of Physics and Technology, Dolgoprudniy, Moscow Region, Russia
3. Moscow State Medical Stomatological University, Moscow, Russia
4. Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudniy, Moscow Region, Russia
Section: Clinical and Diagnostic Research
DOI: 10.18097/PBMC20166206708      PubMed Id: 28026816
Year: 2016  Volume: 62  Issue: 6  Pages: 708-714
There is a clear need in molecular markers for prostate cancer (PC) risk stratification. Alteration of DNA methylation is one of processes that occur during ÐÑ progression. Methylation-sensitive PCR with high resolution melting curve analysis (MS-HRM) can be used for gene methylation analysis in routine laboratory practice. This method requires very small amounts of DNA for analysis. Numerous results have been accumulated on DNA methylation in PC samples analyzed by the Infinium HumanMethylation450 BeadChip (HM450). However, the consistency of MS-HRM results with chip hybridization results has not been examined yet. The aim of this study was to assess the consistency of results of GSTP1, APC and RASSF1 gene methylation analysis in ÐÑ biopsy samples obtained by MS-HRM and chip hybridization. The methylation levels of each gene determined by MS-HRM were statistically different in the group of PC tissue samples and the samples without signs of tumor growth. Chip hybridization data analysis confirmed the results obtained with the MS-HRM. Differences in methylation levels between tumor tissue and histologically intact tissue of each sample determined by MS-HRM and chip hybridization, were consistent with each other. Thus, we showed that the assessment of GSTP1, APC and RASSF1 gene methylation analysis using MS-HRM is suitable for the design of laboratory assays that will differentiate the PC tissue from the tissue without signs of tumor growth.
Download PDF:  
Keywords: prostate cancer, DNA methylation, HRM, GSTP1, APC, RASSF1
Citation:

Skorodumova, L. O., Babalyan, K. A., Sultanov, R., Vasiliev, A. O., Govorov, A. V., Pushkar, D. Y., Prilepskaya, E. A., Danilenko, S. A., Generozov, E. V., Larin, A. K., Kostryukova, E. S., Sharova, E. I. (2016). GSTP1, APC and RASSF1 gene methylation in prostate cancer samples: comparative analysis of MS-HRM method and Infinium HumanMethylation450 BeadChip beadchiparray diagnostic value. Biomeditsinskaya Khimiya, 62(6), 708-714.
This paper is also available as the English translation: 10.1134/S199075081702007X
References  
 2024 (vol 70)
 2023 (vol 69)
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)